Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

Within the past year, PFE's PEG has been as high as 1.24 and as low as 0.53, with a median of 0.84. Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price ...

Q2 earnings growth for the S&P 500 index of +4.7% improves to +6.7% once the Energy sector’s drag is removed from the aggregate numbers, ... Bank Earnings Outlook Improving.